These data suggest that Ptges inhibitors blocking PGE2 biosynthesis, such as C118 and C934 (ref. 28), which were tested in the current study, as well as EP4 signaling antagonists, may represent good drug candidates for the treatment of prion diseases. The gene discussed is PTGES; the disease is prion disease.